ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0415

Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis

Ellen Romich, Sherry Chou and Rennie Rhee, University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2021

Keywords: ANCA associated vasculitis, Disease Activity, Patient reported outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: ANCA-associated vasculitis (AAV) causes sinus symptoms that impact quality of life. The 22-item Sinonasal Outcome Test (SNOT-22) is a patient-reported outcome measure to assess symptoms and quality of life in chronic rhinosinusitis but has not been well-studied in AAV. We compared SNOT-22 scores during remission and active disease in AAV patients with and without sinus involvement and investigated if SNOT-22 scores can predict subsequent relapse.

Methods: Subjects with AAV (granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) based on 1990 ACR classification criteria or Chapel Hill Consensus Conference nomenclature) and healthy controls were followed longitudinally with measures of disease activity [BVAS/WG, physician global assessment (PGA)], SNOT-22, and treatment. SNOT-22 questions are scored on a 0-5 scale with higher scores for worse symptoms and include 5 subdomains (rhinologic, extra-nasal rhinologic, ear/facial, psychological, sleep). Generalized estimating equations evaluated the association between SNOT-22 scores and disease activity. Models were adjusted for concomitant seasonal allergies and use of antibiotics, immunosuppressive drugs, and sinus rinses.

Results: 159 AAV subjects (106 GPA, 21 MPA, 32 EGPA) with 747 visits (110 active disease visits, mean interval 3.5 months) and 70 controls were included (Table 1). Baseline SNOT-22 total scores were higher in AAV vs. controls (mean (SD): 27.5 (1.6) vs. 15.4 (2.1), p< 0.01) and higher for AAV subjects with vs. without sinus involvement (mean (SD): 30.3 (20.5) vs. 17.8 (13.2), p< 0.01). Adjusted SNOT-22 total scores were significantly higher during active disease vs. remission for GPA and EGPA but not MPA (Figure 1A). Subgroup analyses demonstrated similar results among subjects with a history of sinonasal involvement but not among subjects without baseline sinonasal disease (p=0.3). For all AAV, higher PGA was associated with higher SNOT-22 total (Figure 1B). In GPA, active disease was associated with higher scores in each SNOT-22 subdomain except sleep. Compared to remission visits, active disease was associated with worse scores occurred in the psychological and sleep subdomains for MPA and in the rhinologic subdomain for EGPA (Figure 2). Prior SNOT-22 total scores were not associated with subsequent relapse among all visits, but when limiting visits to those 2 months apart, increase in SNOT-22 score at prior visits was associated with subsequent relapse (adj OR 1.15 per score change of 5, 95% CI: 1.0-1.3, p=0.03).

Conclusion: In AAV, SNOT-22 scores are higher during active disease vs. remission particularly among patients with previous sinus involvement. The subdomains impacted most by disease activity differ by disease type. When measured within 2 months, change in SNOT-22 scores at remission are associated with subsequent relapse. SNOT-22 may be an informative patient-reported outcome measure to monitor disease activity in AAV patients.

Figure 1. A) SNOT_22 total score at remission and active disease visits according to diagnosis. Asterisks indicate significant differences in adjusted model. B) SNOT_22 total score for all AAV subject visits plotted against Physician Global Assessment showing higher disease activity measure corresponds with higher SNOT_22 total score (p<0.001 in adjusted model).

Figure 2. SNOT_22 subdomain scores during remission and active disease. Results demonstrate higher scores during active disease with larger effect on certain subdomains according to diagnosis. Asterisks indicate significant differences in adjusted model.


Disclosures: E. Romich, None; S. Chou, None; R. Rhee, None.

To cite this abstract in AMA style:

Romich E, Chou S, Rhee R. Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/utility-of-the-22-item-sinonasal-outcome-test-patient-reported-outcome-instrument-in-anca-associated-vasculitis/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-the-22-item-sinonasal-outcome-test-patient-reported-outcome-instrument-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences